• Biodesix Makes the Case for VeriStrat Through New Study

    August 31, 2018 “The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).”   Read the full story.  Read more
  • Medical Laboratory Observer: Liquid biopsy and droplet digital PCR offer improvements for lung cancer testing

    August 22, 2018 “…the growing use of ddPCR assays for identifying the subset of patients who should be placed on targeted therapy options is providing carefully measured results with rapid turnaround time for optimal clinical utility. This approach enabled by liquid biopsy means that physicians do not have to wait weeks for genomic information that may enable the ... Read more
  • Molecular Diagnostic Report: Circulating DNA – Utility and Challenges in NSCLC

    August 3, 2018 “Methods for measuring ctDNA, circulating tumour RNA (ctRNA), and circulating proteomic signatures from the blood are non-invasive and provide diagnostic and independent prognostic information that can help drive therapeutic strategy, as well as facilitate patient-physician conversations about prognosis and care preferences.” Read the full story.  Read more
  • Clinical Lab Products: Predicting the Effectiveness of Anti-PD-L1 Therapy

    June 19, 2018 “In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians who are evaluating an NSCLC patient’s eligibility for anti-PD-L1 therapy.” Read the full story.  Read more
  • The Pathologist: Has Tumor Profiling Caught Up to Cancer?

    March 20, 2018 “I see ddPCR as the future of personalized cancer therapies. Based on our cancer center’s successful experience with the technology, I believe it is only a matter of time before these kinds of blood-based liquid biopsies become an indispensable method for doctors to categorize a patient’s disease and determine the best course of treatment.” – ... Read more
  • The Future of Droplet Digital PCR

    February 5, 2018 “Liquid biopsies are becoming more and more accepted, particularly by community physicians seeking timely diagnostic test results to inform treatment decisions. The number of treatment options, especially in certain disease states, like lung cancer, are multiplying rapidly, and the demand for testing that can help physicians determine which patients are most likely to benefit from ... Read more
  • Blood-based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry

    December 21, 2017 From Clinical Lab Products: “Measurement of PD-L1 is challenging not only when tissue is lacking, but due to the inherent complexity of immunohistochemistry,” says Pritchett. “The testing approach demonstrated in this study shows promise as a method of assessing PD-L1 in plasma. A more objective measure of PD-L1 status could offer a path to better ... Read more
  • Oncology Times: The Use of Liquid Biopsies in Patients With NSCLC

    November 30, 2017 “Increasingly, medical oncologists work with multidisciplinary teams to diagnose and manage lung cancer cases. Interventional pulmonologists on these teams perform diagnostic workups, obtain tissue biopsies, and play a role in the timely diagnosis and staging of lung cancer (Ann Am Thorac Soc 2015;12(5):742-751). The number of molecular tests that can impact patient treatment is increasing, while ... Read more
  • CAP Today: Revived hopes, fresh challenges with liquid biopsy

    October 23, 2017 CAP Today:  “Liquid biopsy is a reality in oncology today. It’s amazing how rapidly it has become the standard of care. And I think pathology labs everywhere are trying to adapt to it and make themselves ready for this new reality.” Read the article. Read more
  • The Pathologist: Battling Lung Cancer in the Tobacco Belt

    October 15, 2017 “We can now identify a cancer’s mutations and respond with appropriate therapy without the issues inherent in solid tissue biopsy – not only the delays, but also the intratumoral heterogeneity that is often missed when sampling only one or a few tumor sites.” – Dr. Paul Walker Read the full story.  Read more